Employing different routes of immunization and different adjuvants, a large number of hybridomas were produced that secreted monoclonal antibodies (MAbs) against the large envelope glycoprotein (GP90) and the fusion glycoprotein (GP70) of respiratory syncytial virus (RSV). The antigenic specificity of the MAbs was established by immunoblot analysis and radioimmunoprecipitation. Three hybridomas secreting anti-GP90 MAbs were established from mice immunized by intraperitoneal injection of purified RSV in Freund's complete adjuvant. MAbs from these hybridomas did not neutralize viral infectivity. Three other hybridomas established from mice immunized by intraperitoneal inoculation of purified RSV with Bordetella pertussis produced anti-GP90 MAbs that neutralized the virus with or without complement. Similarly three other hybridomas established from mice immunized by infection with RSV via intranasal instillation of the virus produced anti-GP90 MAb that neutralized the virus in the presence and absence of complement. On the other hand, most anti-GP70 MAbs exhibited no neutralizing activity in the absence of complement, although many had low levels of neutralizing activity in the presence of complement, regardless of the type of immunization or the isotype of immunoglobulin. These observations suggest that there may be multiple antigenic sites on GP90, some of which involve a region of the molecule that functions in viral neutralization.
INTRODUCTION
Respiratory syncytial virus (RSV), a major cause of serious respiratory infection in infants and young children (Kim et al., 1973) is an enveloped RNA virus related to the paramyxoviruses (Kingsbury et al., 1978) , and possesses several distinct antigenic glycoproteins (Wunner & Pringle, 1976) . Although several live attenuated and a few inactivated virus candidate vaccines have been tested, there is still no available means of effective immunoprophylaxis (Kim et al., 1969; Belshe et al., 1982) . Thus, there is a clear need to define the important viral antigens involved in evoking a protective immune response, especially those interacting with neutralizing antibody. Several studies using monoclonal and polyclonal antibodies have focused on the fusion glycoprotein (GP70) and the large cell-attachment glycoprotein (GP90) of the virus as target molecules for neutralizing antibody. There is evidence that anti-GP70 antibody can effect neutralization of infectivity. It is reported that 11 of 13 anti-GP70 monoclonal antibodies (MAbs) neutralize viral infectivity (Fernie et aL, 1982) . Other studies (Walsh et al., 1986) have shown that five of these MAbs also inhibit fusion in vitro. Earlier studies (Fernie et al., 1982; Stott et al., 1984) have suggested that MAbs to the large glycoprotein do not neutralize infectivity. However, other studies have suggested neutralizing activity in one of two anti-GP90 MAbs, but neutralization occurred only in the presence of complement (Walsh & Hruska, 1983) . Polyclonal antibody to GP90, on the other hand, appeared to be capable of neutralization without complement (Walsh et al., 1984) .
The present studies were undertaken to determine if the differences in the nature of the MAbs induced are related to the nature or route of RSV infection employed. Experiments reported here analyse the important protective epitopes of RSV glycoproteins, employing MAbs derived by three different methods of immunization.
METHODS
Virus and cells. HEp-2 cell culture monolayers were maintained in MEM supplemented with 10~ heatinactivated foetal calf serum. The Long strain of human RSV was grown in HEp-2 cell cultures to stock titres of 107 p.f.u./ml. Preparations of RSV were purified by polyethylene glycol precipitation followed by band purification in a discontinuous sucrose gradient (Ueba, 1980) .
Hybridomaproduction. BALB/c mice, 6 to 7 weeks old, were immunized with purified RSV in accordance with the following three schedules. In the first immunization schedule, 30 ~tg of purified RSV mixed with complete Freund's adjuvant (Difco) was given intraperitoneally (i.p.), followed 3 weeks later by injection i.p. of 15 ~g of purified RSV without adjuvant. The animals were sacrificed after 3 days and the spleens removed. Isolated spleen cells were fused with NS-1 myeloma cells using polyethylene glycol (Fazekas de St. Groth & Scheidegger, 1980) . Hybridomas were selected on hypoxanthine-aminopterin-thymidine medium and screened for RSV antibody. Hybridoma supernatants diluted 1:5 in phosphate-buffered saline (PBS) were tested by indirect immunofluorescence (IFA) on acetone-fixed HEp-2 cells infected with RSV. Fluorescein-conjugated goat anti-mouse Ig, heavy and light chain-specific antisera, (Cappel Laboratories) were used. In the second schedule, 35 vtg of the same RSV antigen as employed in the first immunization schedule was mixed with 2 x 109 killed Bordetella pertussis organisms and injected i.p. After 2 weeks, 15 ~tg of the same antigen in saline was injected i.p. Three days later, the mice were sacrificed and hybridomas were prepared as outlined above. In the third immunization schedule, mice were inoculated intranasally with 2 x 105 p.f.u, of RSV and after 4 weeks, 15 ~tg of purified RSV in saline was injected i.p. Three days later, the mice were sacrificed and the spleen cells were fused to form hybridomas as described previously.
The hybridomas obtained from animals immunized by the different procedures were additionally screened for antibody by a fluorescent focus neutralization assay (Taniguchi et al., 1985) . In this assay 500 f.f.u, of RSV in 0.025 ml of culture fluid were mixed with hybridoma supernatant containing fresh guinea-pig serum to yield a 1:2 dilution of the supernatant. The mixture was incubated for 1 h at 37 °C and inoculated onto HEp-2 cell monolayers in 96-well plastic plates (Costar). After adsorption and addition of culture medium, the plates were incubated for 48 h at 36 °C in 5~ CO2. The monolayers were fixed with acetone and stained with a fluorescein-conjugated bovine anti-RSV serum (Burroughs-Wellcome). Hybridoma supernatants that reduced f.f.u, by 60~ were considered to contain anti-RSV antibody. All the hybridomas that were found to be secreting antibody by the IFA or the fluorescent focus neutralization assay were expanded and cloned by the limiting dilution method at one cell per well. Several clones were recloned by the same procedure. Supernatant fluids from clones used in the study contained approximately 0.2 mg/ml of Ig as determined by radial immunodiffusion using subclass isotype-specific plates (Meloy Laboratories, Springfield, Va., U.S.A.).
Characterization of MAbs. The specificity of the MAbs for viral polypeptides was determined by immunoblot analysis (Gruber & Levine, 1985) . Briefly, purified RSV was disrupted by boiling for 2 min in the sample buffer (0.1 M-Tris-HCI pH 6-8, 2% SDS, 2~ 2-mercaptoethanol and 20~ glycerol) and the polypeptides were separated by SDS-PAGE on 10~ gels. The separated proteins were transferred to nitrocellulose paper by electrophoresis in 0.19 r,l-glycine, 0.025 M-Tris buffer pH 8.3 and 20~ methanol, for 45 min in a Transphor apparatus (Hoefer Scientific Instruments, San Francisco, Ca., U.S.A.). The nitrocellulose was blocked with a solution of 0.05 M-Tris-HCI, 0" l 5 M-N aCt and 2% Tween 20 pH 10-2. Membranes were then treated with a 1:10 dilution of hybridoma supernatant and incubated for 1 h at room temperature. After washing, the nitrocellulose was treated with a 1:1000 dilution of horseradish peroxidase-conjugated goat anti-mouse IgG or IgM (Bio-Rad) for 1 h at room temperature. The paper was washed and treated with freshly prepared 4-chloro-l-naphthol, 60 mg in 20 ml methanol, 80 ml PBS and 15 Ix150~ H20 z to develop the pattern. Uninfected HEp-2 cell cultures prepared in the same manner as purified RSV were included as controls in all immunoblot experiments. Antigenic specificity of the MAbs for RSV glycoproteins was also determined by radioimmunoprecipitation in a manner similar to that described previously (Walsh & Hruska, 1983) .
Neutralizing antibody. Antibody titres of hybridoma tissue culture fluids were determined by a plaque reduction assay using the RSV Long strain and HEp-2 cell culture monolayers in 24-well microtitre plates (Fernie et al., 1982; Walsh & Hruska, 1983) . Complement-enhanced neutralization was performed in parallel by the inclusion of a 1 : 20 dilution of fresh guinea-pig serum in the virus-antibody mixtures.
Immunofluorescence. Staining of RSV-infected HEp-2 cells was carried out by the indirect procedure. Supernatant fluids were diluted 1 : 10 and placed on the washed infected cell monolayers and on uninfected control cells. After incubation (1 h at 37 °C) and washing, the cells were treated with a ftuorescein isothiocyanateconjugated rabbit anti-mouse IgG or IgM reagent (Cappel Laboratories).
RESULTS

Characteristics of RSV GP90-specific clones
Nine hybridomas secreting anti-RSV antibody were established from animals immunized by the three procedures (Table 1) . Of these, three clones (A, B and C) secreted MAbs reactive with GP90 as determined by radioimmunoprecipitation or immunoblot analysis (Table 1, Fig. 1 ). Hybridomas established from immunized animals were screened using the IFA and fluorescent focus neutralization assay in order to detect efficiently the production of neutralizing MAbs. Several clones from animals immunized by the second and third procedures were positive for neutralizing MAbs. The patterns of the immunoblot reactions showed that all nine MAbs recognized a 90K protein. The reaction band in all cases was wide and diffuse in appearance. In addition to the 90K reactivity two antibodies also recognized a 50K protein (Fig. 2, lane 1) . Of additional interest is the observation that supernatants from normal HEp-2 cell cultures without any RSV infection exhibited distinct reactivity with the anti-GP90 MAb (B 13) as shown in Fig.  2 , lane 2. The reactivity of this MAb was limited to recognition of a 63K protein in the uninfected HEp-2 cell preparations.
Results of neutralization for different MAbs are shown in Table 1 . MAbs in group I secreted by hybridomas from mice immunized with purified RSV in Freund's complete adjuvant were associated with the IgG1 isotype and directed against RSV GP90. However, these antibodies failed to neutralize infectivity. On the other hand, group II and group III MAbs all neutralized infectivity in the presence of complement. Two of the three group II MAbs were also capable of neutralizing infectivity without complement. One of these antibodies was the IgM reactive with the 50K viral protein and the 63K uninfected HEp-2 cell protein referred to above (Fig. 2) .
All antibodies produced had predictable patterns of fluorescence characterized by peripheral membrane staining in unfixed infected cells. The reaction patterns often showed filamentous extensions protruding from the cell surface. Although not shown, generalized diffuse cytoplasmic staining was observed on acetone-fixed infected cells as described previously (Stott et al., 1984; Walsh & Hruska, 1983 :~ Antigen specificity was determined by immunoblot analysis of RSV proteins and radioimmunoprecipitation using [35S]methionine-labelled RSV.
§ Neutralizing activity was determined by 50~ plaque reduction neutralization of hybridoma culture fluids tested in the presence or absence of complement. 
Characteristics of RS V GP70-specific clones
Of the RSV antibody-secreting hybridomas, two clones were found to secrete MAbs reactive against GP70. The anti-GP70 MAbs consistently recognized 48K and 24K antigens when tested by radioimmunoprecipitation (Table 2 ). The specific antibody activity was associated with immunoglobulin isotypes IgG1 in four, IgG2 in seven and IgG3 in one antibody-producing clones (Table 2) .
Only two MAbs exhibited neutralizing activity without complement (B2-1 and B9, Table 2 ). On the other hand, eight of 12 MAbs tested demonstrated neutralizing antibody activity in the presence of complement (Table 2) . Several MAbs exhibited enhancement of neutralizing activity by addition of complement. Interestingly, the presence of neutralizing activity was not restricted to any one immunoglobulin isotype or IgG subclass (Table 2 ). However, it should be pointed out that no anti-GP70 clones could be generated after intranasal immunization in group III. Unlike anti-GP90, no reactivity was observed between the anti-GP70 MAbs and uninfected HEp-2 cell proteins. In the present studies, eight of the 12 anti-GP70 MAbs exhibited neutralizing activity with complement, regardless of the immunoglobulin isotype or the type of adjuvants employed during immunization. These observations are similar to those reported recently by others (Fernie et al., 1982) . For anti-GP90 activity, however, the MAbs exhibited three distinct patterns of reaction. Seven of the nine MAbs reacted only with a 90K protein. These reactions showed a characteristically wide and diffuse band (Fig. 1) , similar to reactions reported for immunoprecipitation analysis of the 90K glycoprotein by other workers (Fernie et aL, 1982; Walsh & Hruska, 1983; Walsh et al., 1984) . Two MAbs also detected a 50K protein in addition to the 90K protein. Earlier studies have described MAbs reacting with the 90K protein which also reacted with a 50K fragment (Fernie et al., 1982) . This was suggested to be a result of the MAb recognizing an epitope on a 50K cleavage product of proteolysis of the 90K protein. One of our two MAbs reacting with the 90K and 50K proteins also reacted with a 63K protein in the preparation from uninfected HEp-2 cells. We are not aware of any reports of MAbs to RSV proteins that react with tissue culture cellular components. The reaction may be an example of cross-reactivity between certain host proteins and viral proteins. It has been reported (Srinivasappa et al., 1986) , that approximately 3.5 ~ of MAbs to various other viruses recognize epitopes of certain host proteins. Interestingly, most cross-reactive MAbs reported previously are associated with IgM isotype. Similar cross-reactivity was observed in our studies.
The present study is the first report of MAbs reactive with RSV GP90 that appear to mediate neutralization of infectivity without the use of complement. Previous reports have described non-neutralizing or complement-dependent neutralizing activity for MAbs against GP90. In these cases, none of the antibodies reacting with GP90 were capable of neutralizing RSV without complement (Fernie et al., 1982; Walsh & Hruska, 1983) . One of the MAbs in the latter study was able to neutralize infectivity only minimally in the presence of complement. The antibody prepared in group III after intranasal infection resulted in neutralization in the presence as well as in the absence of complement. Addition of complement did not enhance the titre of neutralizing activity. These results suggest the possible existence of several functionally defined antigenic sites on the GP90 glycoprotein. Group I MAbs did not effect neutralization and showed reaction only with the 90K protein by immunoblot analysis. On the other hand, two sets of Group II MAbs neutralized RSV infectivity. One of the MAbs in this group (B7) elicited little or no neutralization of infectivity in the absence of complement.
Analysis of the neutralization data with immunoblot testing suggests at least one antigenic site defined by MAbs A1, A3 and A4 which when combined with antibody did not result in neutralization. A second functionally defined site is suggested by the reactivity of the B14, C2 and C3 MAbs. These effected neutralization without complement. In fact, neutralization was not significantly enhanced by complement. A third site of potential interaction is suggested by the reaction patterns of the B 13 and C 1 MAbs. These antibodies effected neutralization in a manner similar to B 14, C2 and C3; however B 13 and C 1 both recognized a site found on the 50K cleavage product, a reaction not seen with the other MAbs in the study. Finally, the crossreactivity exhibited by B13 for a host protein could reflect the existence of a second epitope within the site functionally defined by C 1 and B 13. These MAbs may also function by blocking virion attachment. The B7 MAb resembles the complement-dependent neutralizing MAb reported previously (Walsh & Hruska, 1983) , although the magnitude of complement-dependent neutralization was significantly higher (1:2048) in their studies using ascites fluid. These studies seem to define another site, one which may lie close to the virion envelope and bring about neutralization.
In a recent study of eight non-neutralizing MAbs reactive with GP90, three antigenic sites were defined, one of which possibly contained three epitopes (Anderson et al., 1986) . These authors comment on the apparently greater number of antigenic sites on GP90 compared to GP70 (the fusion protein) and have suggested a greater diversity among RSV strains for GP90 antigenic sites. The data in our study indicate that GP90 may possess antigenic determinants involved in virus infectivity. When presented appropriately to the immune system, they may stimulate two and possibly more responses that produce neutralizing antibodies. Our studies are based largely on neutralization of infectivity with or without complement. Therefore, the conclusions drawn are only tentative. Further identification and topological localization of the epitopes should be possible with specific competition binding studies. Definition of such specific viral epitopes should aid in efforts to develop an effective vaccine for RSV. These studies were supported by grants from the National Institute of Allergy and Infectious Diseases (AI-15939-07) and the National Institute of Child Health and Human Development (HD-15943-01).
